WAVE Life Sciences에 대한 매도 수량은 투자자에게 WAVE Life Sciences의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

WAVE Life Sciences (NASDAQ:WVE) 주식, 공매도 수량 보고

WAVE Life Sciences

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Mid Cap

News

Movers

Trading Ideas

$BTC

AMZN

CLSK

IONQ

LBPH

OKLO

WOLF

이들 7개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?

오클로, 클린스파크 및 울프스피드는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (10월 14일-18일)

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences Ltd

Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Outperform and raises the price target from $19 to $22.

Price Target

Analyst Ratings

Mizuho Maintains Outperform on WAVE Life Sciences, Raises Price Target to $22

HC Wainwright &amp; Co. analyst Andrew Fein reiterates WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy and maintains $22 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on WAVE Life Sciences, Maintains $22 Price Target

Truist Securities analyst Joon Lee maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy and raises the price target from $17 to $36.

Truist Securities Maintains Buy on WAVE Life Sciences, Raises Price Target to $36

WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.28) by 67.86 percent.

Earnings

Earnings Misses

WAVE Life Sciences Q3 2024 GAAP EPS $(0.47) Misses $(0.28) Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect WAVE Life Sciences to report an earnings per share (EPS) of $-0.29.
Anticipation surrounds WAVE Life Sciences's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS missed by $0.04, leading to a 5.75% drop in the share price on the subsequent day.
Here's a look at WAVE Life Sciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.21</td>
<td>-0.21</td>
<td>-0.23</td>
<td>-0.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.25</td>
<td>-0.24</td>
<td>-0.15</td>
<td>0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>-2.0%</td>
<td>8.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731333748_0.png" alt="eps graph" />
<h3>Tracking WAVE Life Sciences's Stock Performance</h3>
Shares of WAVE Life Sciences were trading at $16.44 as of November 08. Over the last 52-week period, shares are up 202.21%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/WVE/earnings">To track all earnings releases for WAVE Life Sciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: WAVE Life Sciences's Earnings Preview

B. Riley Securities analyst Madison El-Saadi maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy and raises the price target from $19 to $22.

B. Riley Securities Maintains Buy on WAVE Life Sciences, Raises Price Target to $22

WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s
Recent proof-of-mechanism data for WVE-006 unlocked Wave's best-in-class RNA editing capabilities; three new wholly owned RNA editing programs targeting PNPLA3, LDLR and APOB are first-in-class approaches to address significant unmet needs in cardiometabolic diseases
Wave plans to have five GalNAc-RNA editing or GalNAc-siRNA programs in the clinic by 2026
Wave's clinically validated platform continues to lead on the improvement of intracellular delivery using novel chemistry, including PN backbone chemistry modifications
&nbsp;

Biotech

General

Wave Life Sciences Highlights Growing Pipeline At Research Day

RBC Capital analyst Luca Issi maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Sector Perform and raises the price target from $7 to $15.

RBC Capital Maintains Sector Perform on WAVE Life Sciences, Raises Price Target to $15

These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Oklo Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) stock gained 99.23% last week. Nuclear-linked stocks gained after Amazon Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) AWS <a href="https://www.benzinga.com//node/41358363" target="_blank" rel="noreferrer noopener">announced plans to invest</a> over $500 million in nuclear power.</li>
<li>Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) shares jumped 67.35% after the company achieved its first-ever therapeutic RNA editing in humans from its RestorAATion-2 trial of WVE-006 for <a href="https://www.benzinga.com//node/41359843" target="_blank" rel="noreferrer noopener">Alpha-1 antitrypsin deficiency</a>. Several analysts raised the price <a href="https://www.benzinga.com/quote/wve/analyst-ratings" target="_blank" rel="noreferrer noopener">target on the stock</a>.</li>
<li>Longboard Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>) gained 52.21% after the company announced it would be acquired by Lundbeck <a href="https://www.benzinga.com//node/41313129" target="_blank" rel="noreferrer noopener">for $60 per share in cash</a>.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares rocketed 42.44% after signing a non-binding preliminary memorandum of terms for up to $750 million in proposed direct funding under <a href="https://www.benzinga.com//node/41339603" target="_blank" rel="noreferrer noopener">the CHIPS and Science Act</a>.</li>
<li>CleanSpark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) stock upped 34.10% last week after Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com//node/41386011" target="_blank" rel="noreferrer noopener">rose above $67,000</a>.</li>
<li>Telephone and Data Systems, Inc. (NYS: TDS) soared 26.03% after the company announced its subsidiary, United State Cellular Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>), <a href="https://www.benzinga.com//node/41403665" target="_blank" rel="noreferrer noopener">selling select spectrum licenses</a> in the AWS and PCS bands.</li>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares increased 15.31%. The company will report third-quarter <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">financial results on November 6</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com//node/41418999" target="_blank" rel="noreferrer noopener">NIO, ASML, And CVS Health Are Among Top 10 Large Cap Losers Last Week (Oct 14-18): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41418879/coinbase-united-airlines-and-sofi-tech-are-among-top-11-large-cap-gainers-last-week-oct-14-18-are-" target="_blank" rel="noreferrer noopener">Coinbase, United Airlines And Sofi Tech Are Among Top 11 Large Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?</a></li>
</ul>
Photo Courtesy of Oklo

Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587639df5064ed0001400135/david-manthey">Baird analyst David Manthey</a> upgraded the rating for W.W. Grainger, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) from Neutral to Outperform and raised the price target from $975 to $1,230. Grainger shares closed at $1,085.57 on Tuesday. <a href="https://www.benzinga.com/quote/GWW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst David Begleiter upgraded Westlake Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) from Underperform to Neutral and boosted the price target from $151 to $159. Westlake shares closed at $141.80 on Tuesday. <a href="https://www.benzinga.com/quote/WLK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Atif Malik upgraded the rating for Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) from Neutral to Buy and increased the price target from $52 to $62. Cisco shares closed at $54.08 on Tuesday. <a href="https://www.benzinga.com/quote/CSCO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cleveland Research upgraded the rating for SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) from Neutral to Buy. SAP shares closed at $229.52 on Tuesday. <a href="https://www.benzinga.com/quote/SAP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Steven Seedhouse upgraded Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) from Outperform to Strong Buy and increased the price target from $13 to $22. WAVE Life Sciences shares closed at $8.56 on Tuesday. <a href="https://www.benzinga.com/quote/WVE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CSCO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-1024x517.png" alt="" class="wp-image-599072" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-1024x517.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-768x388.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130.png 1297w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More:<a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h">United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday</a></li>
</ul>

Upgrades

Markets

CSCO

This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Raymond James analyst Steven Seedhouse upgrades WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) from Outperform to Strong Buy and raises the price target from $13 to $22.

Raymond James Upgrades WAVE Life Sciences to Strong Buy, Raises Price Target to $22

Wells Fargo analyst Tiago Fauth maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Overweight and raises the price target from $11 to $22.

Wells Fargo Maintains Overweight on WAVE Life Sciences, Raises Price Target to $22

Leerink Partners analyst Mani Foroohar maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Outperform and raises the price target from $20 to $22.

Leerink Partners Maintains Outperform on WAVE Life Sciences, Raises Price Target to $22

Whales with a lot of money to spend have taken a noticeably bullish stance on WAVE Life Sciences.
Looking at options history for WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 46% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $251,490 and 10, calls, for a total amount of $481,968.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $7.5 to $15.0 for WAVE Life Sciences during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for WAVE Life Sciences options trades today is 608.71 with a total volume of 10,303.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for WAVE Life Sciences's big money trades within a strike price range of $7.5 to $15.0 over the last 30 days.
<h3>WAVE Life Sciences Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729097158_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WVE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.15</td>
<td>$1.7</td>
<td>$1.7</td>
<td>$12.50</td>
<td>$170.0K</td>
<td>1</td>
<td>1.0K</td>
</tr>
<tr>
<td>WVE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.5</td>
<td>$1.95</td>
<td>$2.0</td>
<td>$15.00</td>
<td>$84.8K</td>
<td>3</td>
<td>1.9K</td>
</tr>
<tr>
<td>WVE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.9</td>
<td>$7.5</td>
<td>$7.7</td>
<td>$7.50</td>
<td>$77.0K</td>
<td>510</td>
<td>111</td>
</tr>
<tr>
<td>WVE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.7</td>
<td>$7.4</td>
<td>$7.5</td>
<td>$7.50</td>
<td>$75.0K</td>
<td>510</td>
<td>212</td>
</tr>
<tr>
<td>WVE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$5.9</td>
<td>$5.6</td>
<td>$5.67</td>
<td>$7.50</td>
<td>$56.9K</td>
<td>1.3K</td>
<td>114</td>
</tr>
</tbody>
</table>

<h3>About WAVE Life Sciences</h3>
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
In light of the recent options history for WAVE Life Sciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>WAVE Life Sciences's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 13,020,486, the WVE's price is up by 74.92%, now at $14.97. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 22 days.</li>
</ul>
<h3>Professional Analyst Ratings for WAVE Life Sciences</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $14.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on WAVE Life Sciences with a target price of $7. 
&#x2A; An analyst from B. Riley Securities has revised its rating downward to Buy, adjusting the price target to $11. 
&#x2A; Maintaining their stance, an analyst from B. Riley Securities continues to hold a Buy rating for WAVE Life Sciences, targeting a price of $19. 
&#x2A; An analyst from JP Morgan has revised its rating downward to Overweight, adjusting the price target to $13. 
&#x2A; An analyst from HC Wainwright &amp; Co. has decided to maintain their Buy rating on WAVE Life Sciences, which currently sits at a price target of $22. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for WAVE Life Sciences with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Looking At WAVE Life Sciences's Recent Unusual Options Activity

<h3>Gainers</h3>
<ul>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock rose 503.9% to $9.18 during Wednesday's regular session. The company's market cap stands at $9.4 million. </li>
<li>Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) shares moved upwards by 124.86% to $89.41. The company's market cap stands at $831.3 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares increased by 111.79% to $0.93. The company's market cap stands at $21.9 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares moved upwards by 84.92% to $0.93. The market value of their outstanding shares is at $3.7 million. </li>
<li>WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) stock moved upwards by 75.23% to $15.0. The company's market cap stands at $2.2 billion. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares increased by 54.07% to $7.72. The market value of their outstanding shares is at $112.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) stock declined by 17.4% to $10.41 during Wednesday's regular session. The market value of their outstanding shares is at $1.6 billion. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock fell 15.27% to $1.16. The market value of their outstanding shares is at $198.1 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares decreased by 11.01% to $0.08. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares fell 9.95% to $8.01. The company's market cap stands at $47.2 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock decreased by 8.61% to $0.47. The market value of their outstanding shares is at $9.9 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock fell 8.58% to $0.31. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATNF

BDRX

GNPX

KLTO

KRRO

LGMK

NVAX

QNRX

RBOT

TVGN

12 Health Care Stocks Moving In Wednesday's Intraday Session

WIIM

Wave Life Sciences shares are trading higher after the company announced it achieved its first-ever therapeutic RNA editing in humans from its RestorAATion-2 trial of WVE-006 for Alpha-1 antitrypsin deficiency.

Wave Life Sciences Ltd.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) stock is trading higher on Wednesday after the company revealed proof-of-mechanism data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency (AATD), an inherited genetic disorder that causes low levels of a protein (AAT) that <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41355354/wave-life-sciences-announces-first-ever-therapeutic-rna-editing-in-humans-achieved-in-restoraation" rel="noreferrer noopener">protects the lungs</a>.
The condition can cause lung and liver damage.
WVE-006 is designed to address AATD-related lung disease, liver disease, or both.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41007614/wave-life-sciences-stock-surges-on-promising-interim-data-from-mid-stage-study-of-muscular-disord" rel="noreferrer noopener">Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug</a>.
The company adds that today&#8217;s proof-of-mechanism data are the first-ever clinical demonstration of RNA editing in humans.
These data are from the first single-dose cohort (200 mg) in RestorAATion-2 and include the first two patients with &#8220;ZZ&#8221; AATD (Pi&#x2A;ZZ AATD) to reach day 57.
Individuals with Pi&#x2A;ZZ AATD do not naturally produce wild-type alpha-1 antitrypsin (M-AAT) protein; therefore, the presence of M-AAT protein is confirmation of successful editing of mutant Z-AAT mRNA.
Additionally, restoring 50% M-AAT would be consistent with the heterozygous &#8220;MZ&#8221; genotype with low risk of AATD lung and liver disease.
Circulating wild-type M-AAT protein in plasma reached a mean of 6.9 micromolar at day 15, representing more than 60% of total AAT.
Increases in neutrophil elastase inhibition from baseline were consistent with the production of functional M-AAT.
WVE-006 has been well-tolerated and has a favorable safety profile to date. All adverse events in RestorAATion-2 and the ongoing RestorAATion-1 trial of healthy volunteers are mild to moderate, with no serious adverse events reported.
The RestorAATion-2 trial is ongoing, and Wave expects to share multidose data in 2025.
GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) has the exclusive global license for WVE-006.
Development and commercialization responsibilities will transfer to GSK after Wave completes the RestorAATion-2 study.
Wave is eligible for up to $525 million in milestones <a target="_blank" href="https://www.benzinga.com/general/biotech/22/12/30058379/wave-life-sciences-shares-move-higher-on-therapeutic-pact-with-gsk-targeting-genetic-disorders" rel="noreferrer noopener">and sales-based royalties</a>.
Price Action: WVE stock is up 74.4% at $14.93 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41356844/fda-puts-speed-breaker-on-novavaxs-covidflu-combo-shot-trial-on-concerns-related-to-damaged-nerve" target="_blank" rel="noreferrer noopener">FDA Puts Speed Breaker On Novavax&#8217;s COVID/Flu Combo Shot Trial On Concerns Related To Damaged Nerves</a>.</li>
</ul>
Image created using artificial intelligence via Midjourney.

Health Care

Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans

09:29 EST Wave Life Sciences (WVE) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mov...

Wave Life Sciences files automatic mixed securities shelf

Analyst Joon Lee of Truist Financial maintained a Buy rating on Wave Life Sciences (WVE – Research Report), with a price target of $36.00. Joon Lee...

Wave Life Sciences: Promising Advancements and Strategic Growth Potential Drive Buy Rating

Truist analyst Joon Lee raised the firm's price target on Wave Life Sciences (WVE) to $36 from $17 and keeps a Buy rating on the shares. Wave Life ...

Wave Life Sciences price target raised to $36 from $17 at Truist

Wave Life Sciences Ltd. (WVE) Q3 2024 Earnings Call Transcript

Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating yesterday. Salim Syed's rating is based ...

Positive FDA Feedback and Strategic Advancements Boost Wave Life Sciences' Investment Potential in Huntington's Disease

Wells Fargo analyst Tiago Fauth maintained a Buy rating on Wave Life Sciences (WVE – Research Report) yesterday and set a price target of $22.00. T...

Wave Life Sciences: Buy Rating Affirmed on Promising RNA Programs and Strong Regulatory Pathway

Wave Life Sciences (WVE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H...

Wave Life Sciences Gains Buy Rating from Andrew Fein Amid Promising Trial Advancements and Potential Accelerated Approval Pathways

In a report released yesterday, Madison Elsaadi from B.Riley Financial reiterated a Buy rating on Wave Life Sciences (WVE – Research Report), with ...

Positive Outlook for Wave Life Sciences Amid Strategic Advances and Regulatory Milestones

Wave Life Sciences ( ($WVE) ) just unveiled an announcement. Wave Life Sciences Ltd. is advancing its position in the RNA medicines sector with its...

Wave Life Sciences Advances RNA Medicine Innovations

Mizuho raised the firm's price target on Wave Life Sciences (WVE) to $22 from $19 and keeps an Outperform rating on the shares. The analyst updated...

Wave Life Sciences price target raised to $22 from $19 at Mizuho

Financing

Press Releases

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference

Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024

Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Comments

WAVE Life Sciences

매도 수량

WAVE Life Sciences (NASDAQ:WVE) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌